今年7月，公司宣布与华东医药的全资附属公司中美华东订立合作协议，据此，公司向中美华东授予标的产品在授权地区和授权领域内的排他共同合作开发权；独家市场推广选择权；及上市许可持有人转让的优先权。公司指，此举为集团带来商业利益，因为与中美华东的合作有利于标的产品充分拓展多适应症，释放产品价值；加快标的产品现有III期临床试验的开发进度，并为集团带来更多资金支持。Chunxin Biotech-B (02509) rose more than 7%, as of the deadline of this report, up 7.54%, closing at 24.95 Hong Kong dollars.
According to the Wisdom Finance APP, Chunxin Biotech-B (02509) rose more than 7%, as of the deadline of this report, up 7.54%, closing at 24.95 Hong Kong dollars.
On the news front, in the first half of this year, Chunxin Biotech achieved a revenue of 44.919 million yuan (RMB, the same below); gross profit of 37.756 million yuan. The announcement stated that the revenue came from licensing fees and research service fees for external authorized transactions QX008N and QX004N, reflecting the group's strong research and development capabilities. As of June 30, 2024, the group is able to conduct efficient research and has obtained approvals for 20 INDs over the past 9 years (19 from the National Medical Products Administration and 1 from the FDA), and has won multiple awards recognizing the group's research and development capabilities.
In July this year, the company announced a cooperation agreement with the wholly-owned subsidiary of Huadong Medicine, China Mei Huadong, under which the company granted China Mei Huadong the exclusive joint development rights of the target product in the authorized region and field; the option for exclusive market promotion rights; and the priority right of the marketing authorization holder transfer. The company stated that this move brings commercial benefits to the group, as cooperation with China Mei Huadong is beneficial for the target product to fully expand into multiple indications, unlock the product's value; accelerate the development progress of the ongoing Phase III clinical trials of the target product, and provide more financial support to the group.
